ORAMED PHARMACEUTICALS INC. (ORMP) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -14.52M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 4.74M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-14.52M | (m) | (m) | $4.74M | (m) | (m) |
| 2026-03-31 | $-14.25M | (m) | (m) | $5.77M | (m) | (m) |
| 2025-12-31 | $-15.09M | $2.00M | (m) | $6.38M | (m) | -754.40% |
| 2025-09-30 | $-13.01M | (m) | (m) | $5.85M | (m) | (m) |
| 2025-06-30 | $-13.67M | (m) | (m) | $6.94M | (m) | (m) |
| 2025-03-31 | $-14.32M | (m) | (m) | $7.35M | (m) | (m) |
| 2024-12-31 | $-12.78M | (m) | (m) | $6.32M | (m) | (m) |
| 2024-09-30 | $-13.06M | (m) | (m) | $6.63M | (m) | (m) |
| 2024-06-30 | $-12.87M | (m) | (m) | $5.34M | (m) | (m) |
| 2024-03-31 | $-13.52M | (m) | (m) | $5.72M | (m) | (m) |
| 2023-12-31 | $-15.77M | $1.34M | (m) | $8.97M | (m) | -1176.79% |
| 2023-09-30 | $-21.63M | $2.02M | (m) | $14.48M | (m) | -1070.36% |
| 2023-06-30 | $-26.93M | $2.70M | (m) | $18.87M | (m) | -996.23% |
| 2023-03-31 | $-34.55M | $2.70M | (m) | $26.23M | (m) | -1278.36% |
| 2022-12-31 | $-40.60M | $2.70M | (m) | $27.64M | (m) | -1501.96% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-11-30 | $-26.46M | $2.70M | (m) | $21.63M | (m) | -978.76% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-08-31 | $-24.22M | $2.70M | (m) | $20.99M | (m) | -896.15% |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-05-31 | $-19.83M | $2.70M | (m) | $18.11M | (m) | -734.17% |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-02-28 | $-15.99M | $2.70M | (m) | $14.54M | (m) | -591.85% |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-11-30 | $-15.15M | $2.71M | (m) | $13.99M | (m) | -559.23% |
| 2020-08-31 | $-11.76M | $2.71M | (m) | $10.23M | (m) | -433.84% |
| 2020-05-31 | $-11.09M | $2.71M | (m) | $9.47M | (m) | -409.04% |
| 2020-02-29 | $-12.89M | $2.71M | (m) | $11.40M | (m) | -475.43% |
| 2019-11-30 | $-12.42M | $2.70M | (m) | $11.20M | (m) | -459.49% |
| 2019-08-31 | $-14.63M | $2.70M | (m) | $13.52M | (m) | -541.29% |
| 2019-05-31 | $-15.44M | $2.64M | (m) | $14.06M | (m) | -584.92% |
| 2019-02-28 | $-15.89M | $2.57M | (m) | $14.39M | (m) | -617.40% |
| 2018-11-30 | $-15.44M | $2.51M | (m) | $14.00M | (m) | -614.45% |
| 2018-08-31 | $-13.53M | $2.45M | (m) | $11.98M | (m) | -552.35% |
| 2018-05-31 | $-13.23M | $2.45M | (m) | $11.78M | (m) | -540.00% |
| 2018-02-28 | $-10.85M | $2.45M | (m) | $9.85M | (m) | -442.90% |
| 2017-11-30 | $-11.11M | $2.46M | (m) | $10.26M | (m) | -451.97% |
| 2017-08-31 | $-10.77M | $2.46M | (m) | $10.28M | (m) | -438.56% |
| 2017-05-31 | $-8.56M | $-909.00K | (m) | $4.88M | (m) | 942.02% |
| 2017-02-28 | $-11.41M | $1.74M | (m) | $9.98M | (m) | -656.99% |
| 2016-11-30 | $-10.06M | $31.00K | (m) | $7.26M | (m) | -32454.84% |
| 2016-08-31 | $-10.01M | $641.00K | (m) | $7.71M | (m) | -1561.62% |
| 2016-05-31 | $6.12M | (m) | (m) | $-3.21M | (m) | (m) |
| 2016-02-29 | $6.60M | (m) | (m) | $-4.01M | (m) | (m) |
| 2015-11-30 | $6.84M | (m) | (m) | $-4.18M | (m) | (m) |
| 2015-08-31 | $7.38M | (m) | (m) | $-4.78M | (m) | (m) |
| 2015-05-31 | $-4.95M | (m) | (m) | $2.44M | (m) | (m) |
| 2015-02-28 | $-7.13M | (m) | (m) | $4.29M | (m) | (m) |
| 2014-11-30 | $-6.64M | (m) | (m) | $3.83M | (m) | (m) |
| 2014-08-31 | $-5.91M | (m) | (m) | $3.28M | (m) | (m) |
| 2014-05-31 | $-5.23M | (m) | (m) | $2.81M | (m) | (m) |
| 2014-02-28 | $-4.67M | (m) | (m) | $2.55M | (m) | (m) |
| 2013-11-30 | $-4.74M | (m) | (m) | $2.63M | (m) | (m) |
| 2013-08-31 | $-4.30M | (m) | (m) | $2.27M | (m) | (m) |
| 2013-05-31 | $-4.26M | (m) | (m) | $2.51M | (m) | (m) |
| 2013-02-28 | $-3.47M | (m) | (m) | $1.93M | (m) | (m) |
| 2012-11-30 | $-3.15M | (m) | (m) | $1.89M | (m) | (m) |
| 2012-08-31 | $-2.88M | (m) | (m) | $1.68M | (m) | (m) |
| 2012-05-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-02-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-11-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-08-31 | $-2.44M | (m) | (m) | $1.16M | (m) | (m) |
| 2011-05-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-02-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-11-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |